Regulated necrosis in kidney ischemia-reperfusion injury

Kidney Int. 2019 Aug;96(2):291-301. doi: 10.1016/j.kint.2019.02.009. Epub 2019 Mar 7.

Abstract

Ischemia-reperfusion injury (IRI) is the outcome of an inflammatory process that is triggered when an organ undergoes a transient reduction or cessation of blood flow, followed by re-establishment of perfusion. In the clinical setting, IRI contributes to significant acute kidney injury, patient morbidity and mortality, and adverse outcomes in transplantation. Tubular cell death by necrosis and apoptosis is a central feature of renal IRI. Recent research has challenged traditional views of cell death by identifying new pathways in which cells die in a regulated manner but with the morphologic features of necrosis. This regulated necrosis (RN) takes several forms, with necroptosis and ferroptosis being the best described. The precise mechanisms and relationships between the RN pathways in renal IRI are currently the subject of active research. The common endpoint of RN is cell membrane rupture, resulting in the release of cytosolic components with subsequent inflammation and activation of the immune system. We review the evidence and mechanisms of RN in the kidney following renal IRI, and discuss the use of small molecule inhibitors and genetically modified mice to better understand this process and guide potentially novel therapeutic interventions.

Keywords: acute kidney injury; apoptosis; ferroptosis; ischemia-reperfusion injury; kidney transplantation; necroptosis; necrosis.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / pathology*
  • Acute Kidney Injury / prevention & control
  • Animals
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Clinical Trials, Phase II as Topic
  • Disease Models, Animal
  • Epithelial Cells / pathology
  • Ferroptosis / drug effects
  • Ferroptosis / genetics
  • Humans
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation / adverse effects*
  • Kidney Tubules / cytology
  • Kidney Tubules / pathology*
  • Mice
  • Mice, Transgenic
  • Microvessels / drug effects
  • Microvessels / pathology*
  • Necroptosis / drug effects
  • Necroptosis / genetics
  • Necrosis / etiology
  • Necrosis / pathology
  • Oxazepines / pharmacology
  • Oxazepines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinases / genetics
  • Protein Kinases / metabolism
  • Randomized Controlled Trials as Topic
  • Receptor-Interacting Protein Serine-Threonine Kinases / genetics
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / genetics
  • Reperfusion Injury / drug therapy
  • Reperfusion Injury / etiology
  • Reperfusion Injury / pathology*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Treatment Outcome
  • Triazoles / pharmacology
  • Triazoles / therapeutic use

Substances

  • GSK2982772
  • Oxazepines
  • Protein Kinase Inhibitors
  • Triazoles
  • MLKL protein, human
  • MLKL protein, mouse
  • Protein Kinases
  • Receptor-Interacting Protein Serine-Threonine Kinases